//// LINK //// Needham Raises ACAD to $9 Target. posted.
The Street insider 11/27
Needham & Company Upgrades Acadia Pharmaceuticals (ACAD) to Buy
Article Related Press Releases (2) Related Articles (3) Stock Quotes (1) Comments (0
Intra-day Needham & Company upgraded Acadia Pharmaceuticals (NASDAQ: ACAD) from Hold to Buy with a price target of $9, following successful top-line results from its pivotal Phase III trial evaluating the efficacy, tolerability and safety of pimavanserin in patients with Parkinson’s disease psychosis.